Grifols agrees long term loan with the European Investment Bank

Barcelona, October 28, 2015: Grifols (MCE: GRF, MCE: GRF.P and NASDAQ:GRFS), one of the world's largest plasma product manufacturers and a pioneer in the research and development of therapeutic alternatives designed to contribute to both scientific and social development, has agreed a loan for 100 million euros with the European Investment Bank (EIB) following conclusion of financial and legal negotiations, including due diligence.

Grifols will use the EIB loan to support its investment in R&D, focusing primarily on the search for new indications for plasma proteins, including the treatment of Alzheimer's disease, vascular diseases, cardiovascular surgery and arterial thrombosis, amongst others.

Grifols is one of the first European companies to receive a loan from the new European Fund for Strategic Investments (EFSI), also known as the Juncker Plan. This is an initiative supported by the EIB and the European Commission, with the aim of reactivating investment in strategic projects throughout Europe, and its objectives include strengthening R&D in European companies.

Grifols hopes that its successful engagement with the EIB will encourage other Spanish companies to consider this source of funding for their projects.

Key conditions of the loan:

  • Principal (amount borrowed): 100 million euros
  • Interest rate: fixed
  • Tenor: 10 years
  • Grace period: 2 years
  • Date of signature of contract: October 28, 2015

About the European Investment Bank

The European Investment Bank (EIB) is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals.

About Grifols:75 years of serving people's health

Grifols is a global company that has been committed to serving people's health since 1940. In 2015 the company celebrates 75 years of improving people's health and well-being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use.

The company is present in more than 100 countries worldwide and its headquarters are located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donation centers in the U.S., and is a leading producer of plasma-derived biological medicines. Within the field of in vitro diagnostics it is a world leader in transfusion medicine, and has a very strong position in immunology and hemostasis, enabling it to offer integrated solutions to clinical analysis laboratories, blood banks and transfusion centers.

Its sales in 2014 exceeded 3,350 million euros, and it employs approximately 14,000 members of staff. Grifols allocates a share of its income to R&D, an investment that demonstrates the company's commitment to scientific progress.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF).Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ:GRFS). For more information visit:www.grifols.com

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.